Familial dysbetalipoproteinemia E78.2

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

broad beta disease; Dysbetalipoproteinemia familial; Hyperlipoproteinemia type III; Mixed hyperlipoproteinemia; Type III hyperlipoproteinemia

History
This section has been translated automatically.

Gofman et al. 1954

Definition
This section has been translated automatically.

Familial dysbetalipoproteinemia (hyperlipoproteinemia type III according to Fredrickson) is a genetic disorder of fat metabolism (mutation of Apo E2 on chromosome 19). Although the mutation is common, the clinical type is relatively rarely expressed. Therefore, other, primarily exogenous factors are involved.

Occurrence/Epidemiology
This section has been translated automatically.

The apolipoprotein phenotype E2/2 (=Apo E2 homozygosity) is frequently represented with 1/100. However, clinical type III according to Fredrickson is rarely manifested;m:w=2-3:1. The multifactorial disease is found in about 1% of the infarct patients.

Etiopathogenesis
This section has been translated automatically.

The cause is a massive accumulation of chylomicron remnants and Very Low Density Lipoprotein (VLDL) remnants. These occur as part of the exogenous (intestinal) and endogenous (hepatic) triglyceride metabolism after the apolipoprotein (Apo) E containing lipoproteins, for example chylomicron and VLDL, have been split by the endothelial lipoprotein lipase. Under physiological conditions, the resulting remnants, which are still triglyceride, but above all cholesterol-rich, are taken up and metabolised by the liver.

Clinical features
This section has been translated automatically.

The lipid metabolism disorder is characterized by increased cholesterol and triglyceride concentrations in the serum. Cholesterol is measured at 300-800mg/dl, triglycerides at 400- >1000mg/dl.

Diagnosis
This section has been translated automatically.

Targeted testing of the polymorphisms APO E2 and APO E4.

Material: 2 - 5 ml EDTA blood.

Method: DNA extraction, PCR; reverse hybridization

Progression/forecast
This section has been translated automatically.

If familial dysbetalipoproteinemia remains untreated, the risk of developing atherosclerosis, coronary heart disease and/or peripheral arterial occlusive disease increases. The manifestation of the disease is also accelerated by external factors: high-fat diet, age, obesity and diabetes.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 29.10.2020